

LILRB1/CD85j/ILT2 Protein, Human (HEK293, Fc)

Cat. No.:	HY-P70182
Synonyms:	rHuLIR-1/LILRB1, Fc; Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1; LIR-1; Leukocyte Immunoglobulin-Like Receptor 1; CD85 Antigen-Like Family Member J; Immunoglobulin-Like Transcript 2; ILT-2; Monocyte/Macrophage Immunoglobulin-Like Receptor 7; MIR-7; CD85j; LILRB1; ILT2; LIR1; MIR7
Species:	Human
Source:	HEK293
Accession:	D9IDM8 (G24-H458)
Gene ID:	10859
Molecular Weight:	100-120 kDa

PROPERTIES

AA Sequence	G H L P K P T L W A E P G S V I T Q G S P V T L R C Q G G Q E T Q E Y R L Y R E K K T A P W I T R I P Q E L V K K G Q F P I P S I T W E H A G R Y R C Y Y G S D T A G R S E S S D P L E L V V T G A Y I K P T L S A Q P S P V V N S G G N V T L Q C D S Q V A F D G F I L C K E G E D E H P Q C L N S Q P H A R G S S R A I F S V G P V S P S R R W W Y R C Y A Y D S N S P Y E W S L P S D L L E L L V L G V S K K P S L S V Q P G P I V A P E E T L T L Q C G S D A G Y N R F V L Y K D G E R D F L Q L A G A Q P Q A G L S Q A N F T L G P V S R S Y G G Q Y R C Y G A H N L S S E W S A P S D P L D I L I A G Q F Y D R V S L S V Q P G P T V A S G E N V T L L C Q S Q G W M Q T F L L T K E G A A D D P W R L R S T Y Q S Q K Y Q A E F P M G P V T S A H A G T Y R C Y G S Q S S K P Y L L T H P S D P L E L V V S G P S G G P S S P T T G P T S T S G P E D Q P L T P T G S D P Q S G L G R H
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

LILRB1 binds MHC class I and also contain immunoreceptor tyrosine-based inhibitory motifs involved in the intracellular transduction of inhibitory signaling, which establishes them as strong candidates for MHC class I-mediated suppression of phagocytosis^[1].

LILRB1 and PD1 shows nonoverlapping expression patterns across CD8+ TEM and TEMRA subsets, and blocking both pathways synergistically enhanced CD8+ T cell function. LILRB1 is highly expressed by the CD8+ TEMRA subset, which is the most potent population for BiTE molecule-induced toxicity. LILRB1-expressing CD8+ T cells infiltrate solid tumors. LILRB1 blockade increases CD8+ T cell cytolytic activity in vitro^[3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA